Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells

Oncology

Volumn 75, Issue 3-4, 2008, Pages 159-168

  Su, Qingbo ^a   Hu, Sanyuan ^a   Gao, Haidong ^a   Ma, Rong ^a   Yang, Qifeng ^a   Pan, Zhenhua ^a   Wang, Tiantian ^a   Li, Feng ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

AIB1; Breast cancer; Estrogen receptor; HER2; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; PROTEIN PS2; SHORT HAIRPIN RNA; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; DRUG SENSITIVITY; ESTROGEN ACTIVITY; EXPRESSION VECTOR; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; RNA INTERFERENCE;

BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTRADIOL ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; HISTONE ACETYLTRANSFERASES; HUMANS; MOLECULAR SEQUENCE DATA; PRESENILIN-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TAMOXIFEN; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 52649177195     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000159267     Document Type: Article

References (57)

1. Group EBCTsC: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-1467.
2. Hayes DF: Tamoxifen: Dr. Jekyll and Mr. Hyde? J Natl Cancer Inst 2004;96:895-897.
3. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-968.
4. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN: Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 2001;85:1928-1936.
5. Henke RT, Haddad BR, Kim SE, Rone JD, Mani A, Jessup JM, Wellstein A, Maitra A, Riegel AT: Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res 2004;10:6134-6142.
6. Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K, Kimura A, Nakamura Y, Inazawa J, Abe T, Yamagishi H: Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int J Cancer 2000;89:217-223.
7. Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997;11:657-666.
8. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, Brown M: High tumour incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004;6:263-274.
9. Shao W, Keeton EK, McDonnell DP, Brown M: Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc Natl Acad Sci USA 2004;101:11599-11604.
10. Wong LJ, Dai P, Lu JF, Lou MA, Clarke R, Nazarov V: AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines. BMC Cancer 2006;6:111.
11. McIlroy M, Fleming FJ, Buggy Y, Hill AD, Young LS: Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. Endocr Relat Cancer 2006;13:1135-1145.
12. Piccart M, Lohrisch C, Di Leo A, Larsimont D: The predictive value of HER2 in breast cancer. Oncology 2001;61:73-82.
13. Mass R: The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000;27:46-52, 92-100.
14. Dowsett M: Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001;8:191-195.
15. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck, SG FS, Wong J, Allred DC, Clark GM, Schiff R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-361.
16. Shang Y, Brown M: Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-2468.
17. Wang TT, Phang JM: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 1995;55:2487-2489.
18. Ciocca DR, Elledge R: Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 2000;13:1-10.
19. Lohrisch C, Piccart M: An overview of HER2. Semin Oncol 2001;28:3-11.
20. Lahusen T, Fereshteh M, Oh A, Wellstein A, Riegel AT: Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Res 2007;67:7256-7265.
21. Kirkegaard T, McGlynn LM, Campbell FM, Müller S, Tovey SM, Dunne B, Nielsen KV, Cooke TG, Bartlett JM: Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 2007;13:1405-1411.
22. Louie MC, Revenko AS, Zou JX, Yao J, Chen HW: Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity. Mol Cell Biol 2006;26:3810-3823.
23. Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, Ittmann M, Tsai SY, Tsai MJ: SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005;65:7976-7983.
24. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL: Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 2003;10:179-186.
25. Louie MC, Zou JX, Rabinovich A, Chen HW: ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 2004;24:5157-5171.
26. Bloom J, Pagano M: Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003;13:41-47.
27. Mussi P, Yu C, O'Malley BW, Xu J: Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol Endocrinol 2006;20:3105-3119.
28. Schiff R, Massarweh S, Shou J, Osborne CK: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003;9:447S-454S.
29. Dihge L, Bendahl PO, Grabau D, Isola J, Lövgren K, Rydén L, Fernö M: Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat 2008;109:255-262.
30. Ree AH, Landmark BF, Eskild W, Levy FO, Lahooti H, Jahnsen T, Aakvaag A, Hansson V: Autologous down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors in MCF-7 cells: an inverse correlation to progesterone receptor levels. Endocrinology 1989;124:2577-2583.
31. Santagati S, Gianazza E, Agrati P, Vegeto E, Patrone C, Pollio G, Maggi A: Oligonucleotide squelching reveals the mechanism of estrogen receptor autologous down-regulation. Mol Endocrinol 1997;11:938-949.
32. Pink JJ, Jordan VC: Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996;56:2321-2330.
33. Valley CC, Solodin NM, Powers GL, Ellison SJ, Alarid ET: Temporal variation in estrogen receptor-alpha protein turnover in the presence of estrogen. J Mol Endocrinol 2008;40:23-34.
34. Alarid ET, Bakopoulos N, Solodin N: Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol 1999;13:1522-1534.
35. Wijayaratne AL, McDonnell DP: The human estrogen receptor is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 2001;276:35684-35692.
36. Laïos I, Journe F, Laurent G, Nonclercq D, Toillon RA, Seo HS, Leclercq G: Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens. J Steroid Biochem Mol Biol 2003;87:207-221.
37. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP: Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994;8:21-30.
38. Pearce ST, Liu H, Jordan VC: Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (ASP-538) in helix 12. J Biol Chem 2003;278:7630-7638.
39. MacGregor Schafer J, Liu H, Bentrem DJ, Zapf JW, Jordan VC: Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 2000;60:5097-5105.
40. Dayan G, Lupien M, Auger A, Anghel SI, Rocha W, Croisetière S, Katzenellenbogen JA, Mader S: Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha. Mol Pharmacol 2006;70:579-588.
41. Levenson AS, MacGregor Schafer JI, Bentrem DJ, Pease KM, Jordan VC: Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351. J Steroid Biochem Mol Biol 2001;76:61-70.
42. Azorsa DO, Cunliffe HE, Meltzer PS: Association of steroid receptor coactivator AIB1 with estrogen receptor-α in breast cancer cells. Breast Cancer Res Treat 2001;70:89-101.
43. Reiter R, Wellstein A, Riegel AT: An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer. J Biol Chem 2001;276:39736-39741.
44. Xu J, Liao L, Ning G: The steroid receptor coactivator SRC-3 (P/CIP/RAC3/AIB1/ ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci USA 2000;97:6379-6384.
45. Lonard DM, Tsai SY, O'Malley BW: Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins. Mol Cell Biol 2004;24:14-24.
46. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-935.
47. Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Lee MJ, Neoptolemos JP, et al: Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 1994;30A:5-11.
48. Tamargo F, Vizoso F, Lamelas ML, Rodil A, Vérez P, Raigoso P, Mulero M, Vázquez J, Roiz C, Allende MT: Analysis of the cytosolic content of the pS2 protein in breast cancer. Rev Esp Med Nucl 2002;21:28-33.
49. Looi LM, Azura WW, Cheah PL, Ng MH: pS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status. Pathology 2001;33:283-286.
50. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000;89:111-117.
51. Ciocca DR, Elledge R: Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 2000;12:1-10.
52. Nesaretnam K, Jin Lim E, Reimann K, Lai LC: Effect of a carotene concentrate on the growth of human breast cancer cells and pS2 gene expression. Toxicology 2000;151:117-126.
53. Balleine RL, Clarke CL: Expression of the oestrogen responsive protein pS2 in human breast cancer. Histol Histopathol 1999;14:571-578.
54. Crombach G, Ingenhorst A, Göhring UJ, Scharl A, Neuhaus W, Möbus V, Schaeffer HJ: Expression of pS2 protein in breast cancer. Arch Gynecol Obstet 1993;253:183-192.
55. Giamarchi C, Solanas M, Chailleux C, Augereau P, Vignon F, Rochefort H, Richard-Foy H: Chromatin structure of the regulatory regions of pS2 and cathepsin D genes in hormone-dependent and -independent breast cancer cell lines. Oncogene 1999;18:533-541.
56. Prest SJ, May FE, Westley BR: The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J 2002;16:592-594.
57. Lu D, Kiriyama Y, Lee KY, Giguère V: Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors. Cancer Res 2001;61:6755-6761.